MedTrace Logo

Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients

NCT04454307 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-07-02

No results posted yet for this study

Summary

The rationale of the use of tramadol for COVID-19 patients is attributed to its anti-inflammatory, hypocagulatory, antioxidant, cardio-protective, analgesic, antitussive, bactericidal and antidepressant effect.

Conditions

Interventions

DRUG

Tramadol

tramadol 100 mg twice daily for 10 days

OTHER

Standard care delivered in the isolation hospitals.

Oxygen ventilation.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Nahla Elashmawy, PhD · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2020-08-31
Completion
2020-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04454307 on ClinicalTrials.gov